Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02GLD
|
|||
| Former ID |
DIB008204
|
|||
| Drug Name |
MF-101
|
|||
| Synonyms |
DW-700; DW-700); Menopause Formula-101; Estrogen receptor beta agonist (menopausal symptoms), Bionovo; Liquiritigenin (menopausal symptoms), Bionovo
Click to Show/Hide
|
|||
| Indication | Hepatitis virus infection [ICD-11: 1E50-1E51; ICD-9: 573.3] | Phase 3 | [1] | |
| Company |
Bionovo Inc; Daewon Pharm Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Estrogen receptor beta (ESR2) | Target Info | Antagonist | [2] |
| KEGG Pathway | Estrogen signaling pathway | |||
| Prolactin signaling pathway | ||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | |||
| Validated nuclear estrogen receptor beta network | ||||
| Validated nuclear estrogen receptor alpha network | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Ovarian Infertility Genes | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00906308) A Study of MF101 in Postmenopausal Women. U.S. National Institutes of Health. | |||
| REF 2 | MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.